Table 2.
Clinical outcomes according to changes in circulating regulatory T cells
| Variable | Patients with increased circulating regulatory T cells (N = 30) | Patients with decreased circulating regulatory T cells (N = 38) | P value | |
|---|---|---|---|---|
| Response | PR | 4 (13.3) | 9 (23.7) | |
| SD | 7 (23.3) | 15 (39.5) | 0.095 | |
| PD | 19 (63.3) | 14 (36.8) | ||
| Disease control rate | 36.7% | 63.2% | 0.030 | |
| PseudoPD/HyperPD | Pseudoprogression | 1 (3.3) | 7 (18.4) | 0.055 |
| Hyperprogression | 5 (16.7) | 0 (0.0) | 0.009 | |
| Immune-related AEs | Any grade | 11 (36.7) | 10 (26.3) | 0.359 |
| Severe AEs | 8 (26.7) | 7 (18.4) | 0.416 |
Abbreviations: PR partial response, SD stable disease, PD progression disease, PseudoPD pseudoprogression, HyperPD hyperprogression, AEs adverse events